Skip to main content

Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
08/18/2022
In the latest installment of Talking Therapeutics, Dr Jennings shares data on the efficacy of several COVID-19 treatments in solid-organ transplant recipients.
In the latest installment of Talking Therapeutics, Dr Jennings shares data on the efficacy of several COVID-19 treatments in solid-organ transplant recipients.
In the latest installment of...
08/18/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
10/06/2021
This week, Dr Jennings reviews two recently published papers that shed light on the optimal amount of “more” for patients in search of reducing residual cardiovascular risk.
This week, Dr Jennings reviews two recently published papers that shed light on the optimal amount of “more” for patients in search of reducing residual cardiovascular risk.
This week, Dr Jennings reviews...
10/06/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
05/12/2022
In the latest installment of Talking Therapeutics, Dr Jennings explores safety considerations of mavacamten for treating patients with hypertrophic obstructive cardiomyopathy.
In the latest installment of Talking Therapeutics, Dr Jennings explores safety considerations of mavacamten for treating patients with hypertrophic obstructive cardiomyopathy.
In the latest installment of...
05/12/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
03/09/2023
Dr Jennings highlights research from the American College of Cardiology 2023 Annual Meeting, focusing on strategies for using statins and bempedoic acid to reduce low-density lipoprotein cholesterol.
Dr Jennings highlights research from the American College of Cardiology 2023 Annual Meeting, focusing on strategies for using statins and bempedoic acid to reduce low-density lipoprotein cholesterol.
Dr Jennings highlights research...
03/09/2023
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
02/09/2024
In this week’s installment of Talking Therapeutics, Dr Jennings reviews a new study addressing risk reduction in chronic kidney disease with the use of quad therapy.
In this week’s installment of Talking Therapeutics, Dr Jennings reviews a new study addressing risk reduction in chronic kidney disease with the use of quad therapy.
In this week’s installment of...
02/09/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
10/07/2024
In this installment of Talking Therapeutics, we explore whether the novel medication finerenone, which has a demonstrated benefit in patients with kidney disease, can also improve outcomes in patients with HFpEF.
In this installment of Talking Therapeutics, we explore whether the novel medication finerenone, which has a demonstrated benefit in patients with kidney disease, can also improve outcomes in patients with HFpEF.
In this installment of Talking...
10/07/2024
Pharmacy Learning Network
Douglass Jennings
Talking Therapeutics
07/19/2024
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.
In this installment of Talking...
07/19/2024
Pharmacy Learning Network